A Phase 1/2 Study of IDP-121 in Patients With Relapsed/Refractory Hematologic Malignancies

This early-phase study is testing a new drug called IDP-121 in people with blood cancers — specifically chronic lymphocytic leukemia (CLL), B-cell lymphomas, and multiple myeloma — who have already tried other treatments and have run out of standard options. **You may be eligible if...** - You are 18 or older with CLL, B-cell lymphoma, or multiple myeloma - You are no longer eligible for available standard treatments - You have a life expectancy of at least 3 months - Your blood counts and organ function are within acceptable ranges - Your heart function is adequate (ejection fraction above 50%) **You may NOT be eligible if...** - You are pregnant or breastfeeding - You have had another cancer in the past 5 years (excluding minor skin cancers) - You have HIV (unless on effective treatment with undetectable viral load), active hepatitis B or C - You have a history of significant blood vessel disease (clots, peripheral artery disease, vasculitis) - You have significant heart disease or uncontrolled high blood pressure - You had a bone marrow/stem cell transplant in the past 3 months or have active graft-versus-host disease Talk to your doctor to see if this trial is right for you.